1-11 of 11
David Micklem
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Niklas Beumer, Jonas S. Waizenegger, Michael Heuser, Jörg Chromik, Grerk Sutamtewagul, Silke Kapp-Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto M. Lemoli, Daniele G. Mattei, Walter Fiedler, Yesid Alvarado-Valero, David Micklem, Linn H. Nilsson, Noelly Madeleine, Nigel McCracken, Cristina Oliva, Claudia Gorcea-Carson, Lisa-Marie Rieckmann, Jenny Krause, Victoria Gensch, Isabel Ben Batalla, Melanie Janning, Nicola Gagliani, Benedikt Brors, Charles D. Imbusch, Bjorn T. Gjertsen, Sonja Loges
Journal: Blood
Blood (2023) 142 (Supplement 1): 1540.
https://doi.org/10.1182/blood-2023-185499
Published: 2023
Journal Articles

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Sonja Loges, Grerk Sutamtewagul, Michael Heuser, Jörg Chromik, Silke Kapp-Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto M. Lemoli, Daniele Giovanni Mattei, Isabel Ben Batalla, Monica Hellesøy, Jonas Waizenegger, Melanie Janning, Charles D. Imbusch, Niklas Beumer, Austin Rayford, Jaya Nautiyal, Tzivia Berkman-Gottlieb, David Micklem, Hani Gabra, Claudia Gorcea-Carson, James B. Lorens, Walter Fiedler, Yesid Alvarado, Bjorn T. Gjertsen, Lisa-Marie Rieckmann
Journal: Blood
Blood (2021) 138 (Supplement 1): 3410.
https://doi.org/10.1182/blood-2021-147225
Published: 2021
Journal Articles

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Sonja Loges, MD PhD, Michael Heuser, Jörg Chromik, MD, Carlos Enrique Vigil, MD, Peter Paschka, MD, Francesca Re, MD, Nicola Di Renzo, MD, Roberto M. Lemoli, Daniele Giovanni Mattei, MD, Isabel Ben-Batalla, PhD, Monica Hellesoy, PhD, Katherine Lorens, MD, Joseph Birkett, PhD, Stuart McPherson, BSc, Jaya Nautiyal, PhD, David Micklem, PhD, Hani Gabra, MD PhD FRCPE, FRCP, James B. Lorens, PhD, Walter Fiedler, MD, Yesid Alvarado, MD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14.
https://doi.org/10.1182/blood-2020-136566
Published: 2020
Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Sonja Loges, MD, PhD, Michael Heuser, MD, Jörg Chromik, MD, Carlos Enrique Vigil, MD, Peter Paschka, MD, Francesca Re, Nicola Di Renzo, MD, Roberto Massimo Lemoli, MD, Daniele Giovanni Mattei, MD, Isabel Ben Batalla, PhD, Monica Hellesoy, PhD, David Micklem, PhD, Robert J. Holt, PhD, James B. Lorens, PhD, Muhammad Shoaib, MD, Hassan Aly, MD PhD, Wouter Hanekom, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3943.
https://doi.org/10.1182/blood-2019-128683
Published: 2019
Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2672.
https://doi.org/10.1182/blood-2018-99-120380
Published: 2018
Journal Articles

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Sonja Loges, MD PhD, Bjørn Tore Gjertsen, Michael Heuser, MD, Joerg Chromik, Isabel Ben-Batalla, Nuray Akyüz, David Micklem, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1375.
https://doi.org/10.1182/blood.V130.Suppl_1.1375.1375
Published: 2017
Journal Articles

BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles

Loges Sonja, Bjorn T. Gjertsen, Michael Heuser, Jörg Chromik, Isabel Ben Batalla, Nuray Akyüz, PhD, David Micklem, Anthony Brown, Jim Lorens, Maxim Kebenko, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2016) 128 (22): 592.
https://doi.org/10.1182/blood.V128.22.592.592
Published: 2016
Journal Articles

Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia

Monica Hellesøy, PhD, Stein-Erik Gullaksen, Benedicte Sjo Tislevoll, Oda Helen Eck Fagerholt, Hakon Reikvam, MD PhD, Sonja Loges, MD PhD, Jorge Cortes, MD, Michael Heuser, MD, Jörg Chromik, Jørn Skavland, PhD, André Sulen, Øystein Bruserud, MD PhD, Jim Lorens, PhD, Gro Gausdal, PhD, David Micklem, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3995.
https://doi.org/10.1182/blood.V128.22.3995.3995
Published: 2016
Journal Articles

Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324

Monica Hellesøy, PhD, Katarzyna Wnuk-Lipinska, PhD, Anna Boniecka, MSc, Eline Milde Nævdal, Hakon Reikvam, MDPhD, Sonja Loges, MDPhD, Jorge E. Cortes, MD, Jørn Skavland, PhD, Øystein Bruserud, MDPhD, Jim Lorens, PhD, David Micklem, PhD, Gro Gausdal, PhD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4931.
https://doi.org/10.1182/blood.V126.23.4931.4931
Published: 2015
Journal Articles

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Robert Erdmann, PhDMSc, Heather Jorgensen, PhD, Isabel Ben-Batalla, PhD, Nils Kruse, PhD, David Micklem, PhD, Gunhild von Amsberg, MD, Philippe Schafhausen, MD, Alexander Schultze, MD MSc, Mark Wroblewski, MSc, Mascha Binder, Miguel Cubas-Cordova, MSc, Tobias Hadlich, MD, Melanie Janning, MD MSc, Stefanie Sawall, Victoria Gensch, Elaine K Allan, Leena Mukherjee, PhD, Heather Morrison, BSc, Jennifer Cassells, Nicolaus Kroeger, MD, James Lorens, MD, Richard E. Clark, MD, Steffen Koschmieder, MD, Peter Vandenberghe, MD PhD, Tim H. Brümmendorf, MD, Andreas Hochhaus, MD, Peter Carmeliet, MD PhD, Tessa L. Holyoake, MD PhD, Klaus Pantel, MD PhD, Carsten Bokemeyer, MD, Sonja Loges, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4512.
https://doi.org/10.1182/blood.V124.21.4512.4512
Published: 2014
Journal Articles

Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.

Francesco Parlati, Monette Aujay, Siv Lise Bedringaas, Susan Demo, Bjorn Gjertsen, Eileen Goldstein, Jing Jiang, Christopher Kirk, Guy Laidig, James Lorens, Yan Lu, David Micklem, Paulina Ruurs, Kevin Shenk, Catherine Sylvain, Congcong Sun, Tina Woo, Han-Jie Zhou, Mark Bennett
Journal: Blood
Blood (2007) 110 (11): 1599.
https://doi.org/10.1182/blood.V110.11.1599.1599
Published: 2007